Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711496 | 1.00 | HCRTR2 (0.42) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL15944065 | 0.91 | HCRTR1 (0.47) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL15711482 | 0.90 | HCRTR2 (0.40) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL15944067 | 0.89 | HCRTR2 (0.39) | HCRTR2HCRTR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15711497 | 0.89 | HCRTR2 (0.39) | HCRTR2HCRTR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15944068 | 0.82 | HCRTR2 (0.39) | HCRTR2HCRTR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15944028 | 0.82 | HCRTR2 (0.36) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL15711490 | 0.82 | HCRTR2 (0.36) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL15944012 | 0.81 | HCRTR2 (0.43) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL15944078 | 0.79 | HCRTR2 (0.42) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228377-A1 | METHYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140228377-A1 | METHYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228377-A1 | METHYLPIPERIDINE DERIVATIVE | HCRTR1, HCRTR2, MC4R | HCRTR2 2/4885HCRTR1 1/4885NR1I2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.